Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan 15;15(2):759-70.
doi: 10.1016/j.bmc.2006.10.051. Epub 2006 Oct 26.

Programmable oligomers targeting 5'-GGGG-3' in the minor groove of DNA and NF-kappaB binding inhibition

Affiliations

Programmable oligomers targeting 5'-GGGG-3' in the minor groove of DNA and NF-kappaB binding inhibition

David M Chenoweth et al. Bioorg Med Chem. .

Abstract

A series of hairpin oligomers containing benzimidazole (Bi) and imidazopyridine (Ip) rings were synthesized and screened to target 5'-WGGGGW-3', a core sequence in the DNA-binding site of NF-kappaB, a prolific transcription factor important in biology and disease. Five Bi and Ip containing oligomers bound to the 5'-WGGGGW-3' site with high affinity. One of the oligomers (Im-Im-Im-Im-gamma-Py-Bi-Py-Bi-beta-Dp) was able to inhibit DNA binding by the transcription factor NF-kappaB.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Crystal structure of the p50/p65 NF-κB heterodimer bound to the DNA duplex 5′-TGGGGACTTTCC-3′ (ref. 13). The p50 and p65 monomers are represented as gold and dark blue ribbons, respectively. a) Top view looking down the DNA double helix. b) Side view showing the 5′-GGGG-3′ oligomer binding site. GC rich regions are shown in red and AT rich regions are shown in light blue. c) Sequence of DNA bound to NF-κB.
Figure 2
Figure 2
Structures of the (a) pyrrole-benzimidazole internal dimer (-Py-Bi-), (b) imidazole-imidazopyridine internal dimer (-Im-Ip-), and (c) imidazole-imidazopyridine cap (Im-Ip-) in comparison with their respective five membered ring systems. Hydrogen-bonding surfaces to the DNA minor-groove floor are bolded.
Figure 3
Figure 3
Postulated hydrogen-bonding models for the 1:1 polyamide-DNA complexes with their matched sequence and the ball-and-stick representation for compounds 1 and 6 over the 6-base-pair matched binding site (variable region W = A or T). a) Im-Im-Im-Im-γ-Py-Py-Py-Py-β-Dp (1); b) Im-Im-Im-Im-γ-Py-Bi-Py-Bi-β-Dp (2), Im-Im-Im-Ip-γ-Py-Bi-Py-Bi-β-Dp (3), Im-Im-Ip-Im-γ-Py-Bi-Py-Bi-β-Dp (4), Im-Ip-Im-Im-γ-Py-Bi-Py-Bi-β-Dp (5), Im-Ip-Im-Ip-γ-Py-Bi-Py-Bi-β-Dp (6).
Figure 4
Figure 4
Illustration of NF-kB:DNA binding inhibition by oligomer 2.
Figure 5
Figure 5
Quantitative DNase I footprinting experiments in the hairpin motif for polyamides 1, 2, and 3 respectively, on the 278 bp, 5′-end-labelled PCR product of plasmid pEF16: lane 1, intact DNA; lane 2, G and A sequencing reaction; lane 3, DNase I standard; lanes 5–15, 1 pM, 3 pM, 10 pM, 30 pM, 100 pM, 300 pM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM polyamide concentration, respectively. Each footprinting gel is accompanied by the following: (top) Ball-and-stick models of the parent polyamide; and (bottom) Binding isotherms for the four designed sites. θnorm values were obtained according to published methods. A binding model for the hairpin motif is shown centered at the top as a ball-and-stick model with the polyamide bound to its target DNA sequence. Imidazoles and pyrroles are shown as filled and non-filled circles, respectively; Dimer units are represented as rectangles containing either Bi enclosed in a circle representing benzimidazole or Ip in a black box representing imidazopyridine; Beta alanine is shown as a diamond; the gamma-aminobutyric acid turn residue is shown as a semicircle connecting the two subunits.
Figure 6
Figure 6
Quantitative DNase I footprinting experiments in the hairpin motif for polyamides 4, 5, and 6 respectively, on the 278 bp, 5′-end-labelled PCR product of plasmid pEF16: lane 1, intact DNA; lane 2, G and A sequencing reaction; lane 3, DNase I standard; lanes 5–15, 1 pM, 3 pM, 10 pM, 30 pM, 100 pM, 300 pM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM polyamide concentration, respectively. Each footprinting gel is accompanied by the following: (top) Ball-and-stick models of the parent polyamide; and (bottom) Binding isotherms for the four designed sites. θnorm values were obtained according to published methods. A binding model for the hairpin motif is shown centered at the top as a ball-and-stick model with the polyamide bound to its target DNA sequence. Imidazoles and pyrroles are shown as filled and non-filled circles, respectively; Dimer units are represented as rectangles containing either Bi enclosed in a circle representing benzimidazole or Ip in a black box representing imidazopyridine; Beta alanine is shown as a diamond; the gamma-aminobutyric acid turn residue is shown as a semicircle connecting the two subunits.
Figure 7
Figure 7
a) Matched DNA sequence with the p50 protein of NF-κB overlapping the oligomer binding site. Asterisks indicate the location of radio-labeled nucleotides in the probe sequence. b) Mismatch DNA sequence. c) Gel shift screen for compounds 16 at concentrations of 10 and 100 nM. d) Plot of relative NF-κB inhibition for compounds 16.
Figure 8
Figure 8
(Top) Ball-and-stick model for 2 and EC50 value from gel shift experiment. (Middle) Representative NF-κB titration gel (n=3) for 2. (Bottom) Binding isotherm for 2.
Figure 9
Figure 9
Antibody supershift on Match DNA. The NF-κB band is shifted in the presence of anti-p50 or anti-p65 antibody.
Scheme 1
Scheme 1
Synthesis of imidazopyridine-imidazole dimers Im-Ip-OH (9) and Boc-Im-Ip-OH (12). i) 8, PhNO2, 140°C; ii) Oleum, red-fuming HNO3; iii) 8, PhNO2, 140°C; iv) H2, Pd/C, DMF; (Boc)2O, DIEA, DMAP, DMF; 4N KOH, MeOH.
Scheme 2
Scheme 2
Representative solid-phase synthesis of polyamide 6 along with a table of the amino acid building blocks used for the synthesis. Reaction conditions: (i) 80% TFA/DCM; (ii) Boc-Py-Bi-OH (13), HBTU, DIEA, DMF; (iii) Ac2O, DIEA, DMF; (iv) repeat i – iii; (v) 80% TFA/DCM; (vi) Boc-γ-OH (14), HBTU, DIEA, DMF; (vii) Ac2O, DIEA, DMF to provide BR1; (viii) 80% TFA/DCM; (ix) Boc-Im-Ip-OH (12), HBTU, DIEA, DMF; (x) 80% TFA/DCM; (xi) Im-Ip-OH, HBTU, DIEA, DMF; (xii) dimethylaminopropylamine (Dp), 80 °C 2 h; (xiii) preparative HPLC to give 6.

References

    1. Olenyuk BZ, Zhang G, Klco JM, Nickols NG, Kaelin WG, Jr, Dervan PB. Proc Natl Acad Sci USA. 2004;101:16768. - PMC - PubMed
    2. Darnell JE. Nat Rev Cancer. 2002;2:740–748. - PubMed
    3. Pandolfi PP. Oncogene. 2001;20:3116–3127. - PubMed
    4. Dervan PB, Edelson BS. Curr Opin Struct Biol. 2003;13:284–299. - PubMed
    1. Finlay AC, Hochstein FA, Sobin BA, Murphy FX. J Am Chem Soc. 1951;73:341–343.
    2. Arcamone FNV, Penco S, Orezzi P, Nicolella V, Pirelli A. Nature. 1964;203:1064–1065. - PubMed
    1. Kopka ML, Yoon C, Goodsell D, Pjura P, Dickerson RE. Proc Natl Acad Sci USA. 1985;82:1376–1380. - PMC - PubMed
    2. Pelton JG, Wemmer DE. Proc Natl Acad Sci USA. 1989;86:5723–5727. - PMC - PubMed
    3. Wemmer DE. Annu Rev Biomol Struct. 2000;29:439–461. - PubMed
    4. Buchmueller KL, Staples AM, Howard CM, Horick SM, Uthe PB, Minh Le N, Cox KK, Nguyen B, Pacheco KAO, Wilson DW, Lee M. J Am Chem Soc. 2004;127:742–750. - PubMed
    5. Baraldi PG, Bovero A, Fruttarolo F, Preti D, Tabrizi MA, Pavani MG, Romagnoli R. Med Res Rev. 2004;24:475–528. - PubMed
    6. Reddy PM, Toporowski JW, Kahane AL, Bruice TC. Bioorg Med Chem Lett. 2005;15:5531–5536. - PubMed
    1. White S, Szewczyk JW, Turner JM, Baird EE, Dervan PB. Nature. 1998;391:468–471. - PubMed
    1. Kielkopf CL, White S, Szewcyzk JW, Turner JM, Baird EE, Dervan PB, Rees DC. Science. 1998;282:111–115. - PubMed
    2. Kielkopf CL, Bremer RE, White S, Szewczyk JW, Turner JM, Baird EE, Dervan PB, Rees DC. J Mol Biol. 2000;295:557–567. - PubMed

Publication types

MeSH terms

LinkOut - more resources